Alain B. Alfonso

Altered Mucus Barrier Integrity and Increased Susceptibility to Colitis in Mice upon Loss of Telocyte Bone Morphogenetic Protein Signalling

F. Boudreau, N. Perreault, J. Allaire, 2021, Cells.

LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

L. Aldana, A. Blanco, I. Torréns, 2017, Clinical & Experimental Metastasis.

Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate.

A. Blanco, D. Urquiza, I. Torréns, 2019, Vaccine.

Comprehensive Profiling of Early Neoplastic Gastric Microenvironment Modifications and Biodynamics in Impaired BMP-Signaling FoxL1+-Telocytes

F. Boisvert, N. Perreault, J. Raisch, 2022, Biomedicines.

Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16

I. Torréns, M. Granadillo, A. Batte, 2018, Journal of Cellular Immunotherapy.